Imricor Medical Systems, Inc.
Imricor filed an 8-K (Item 2.02) with its Q3 CY2026 Quarterly Activities Report. Revenue was US$188k, up 437% from US$35k a year earlier, driven by the first U.S. NorthStar sale. Net loss narrowed 17% to US$2.9m, and cash stood at US$62.1m at September 30, 2026. The quarter marked the U.S. commercial launch with two pediatric hospital customers and a Philips compatibility declaration.
- Revenue of US$188k, up 437% from US$35k in Q3 CY2025.
- Net loss of US$2.9m, down 17% from US$3.5m a year earlier.
- Cash of US$62.1m (A$90m) at September 30, 2026.
- Rady Children's Hospital and Children's Medical Center Dallas became first two U.S. customers.
- 14 of 15 FDA submissions for the full U.S. platform are complete or under review.
Price data unavailable.
Imricor's first U.S. commercial sales and Philips collaboration mark a potential revenue inflection point for a company with $62.1m cash.
Philips issued a Third Party Product Compatibility Declaration, opening its installed MR base to NorthStar in the U.S. and Europe.
Revenue recognition depends on site installation timing; Children's Medical Center Dallas revenue falls in Q4. Final PMA approval requires completing the VISABL-AFL trial and an FDA pre-approval inspection.